Endurance Exercise & Virtual Reality for Optimizing Cortical Excitability and Neuroplasticity in PD (NCT06133283) | Clinical Trial Compass
RecruitingNot Applicable
Endurance Exercise & Virtual Reality for Optimizing Cortical Excitability and Neuroplasticity in PD
United States16 participantsStarted 2024-02-09
Plain-language summary
This study aims to determine the effects of aerobic exercise as a primer to add-on virtual reality (VR)-based rehabilitation on balance, postural control and neuroplasticity (ability of brain to adapt in structure and function) in individuals with Parkinson's disease (PD). This study will utilize two groups - one group will receive the exercise and VR, while the other group will receive stretching exercise and VR over eight weeks. The study team will administer outcomes at baseline, post-intervention (8 weeks) and follow-up (6 weeks after post-assessment).
Who can participate
Age range18 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Diagnosis of idiopathic PD (ages 18 -85) in Hoehn and Yahr stages 2 - 3.
✓. Subjects need to demonstrate a score of equal to or greater than 23 on the Mini Mental State Examination.
✓. Subjects who have a score of ≤21.5 on the Mini Balance Evaluations Systems Test (miniBESTest).
Exclusion criteria
✕. Subjects with a history of other neurological diseases (i.e., stroke, multiple sclerosis).
✕. Subjects with a history of severe cardiopulmonary disease, uncontrolled hypertension, orthostatic hypotension, uncontrolled diabetes, severe osteoporosis, severe arthritis affecting their lower extremity joints.
✕. Subjects with a history of PD-specific surgical procedures such as deep brain stimulation etc.
✕. Subjects with a history of head injury.
✕. Subjects with a history of seizures or epilepsy.
✕. Subjects who are currently pregnant.
What they're measuring
1
Balance
Timeframe: Baseline, post (8 week), follow-up (14 weeks)
Trial details
NCT IDNCT06133283
SponsorThe University of Texas Health Science Center at San Antonio